Literature DB >> 8625574

Infection of vascularized fibular grafts.

C K Low1, R W Pho, A K Kour, K Satku, V P Kumar.   

Abstract

Between June 1978 and July 1991, 64 limb reconstructions were done using vascularized fibular grafts. Of these, 10 became infected. Five grafts were proven viable, whereas the other 5 were proven nonviable based on the survival of the skin in the composite osteocutaneous graft and from bone scans, angiograms, and biopsies. A distinct difference in the radiologic manifestation and clinical course of the infection was noted between the viable grafts and nonviable grafts. The viable grafts showed radiologic changes of osteomyelitis that were localized, and the graft incorporated, healed with antibiotics, and exhibited graft hypertrophy. In the nonviable grafts, the radiologic changes were extensive, evidence that resorption of the grafts had resulted. This suggests that, because of the poor prognosis associated with infection of the nonviable vascularized fibular grafts, the infected grafts should be removed early to minimize the morbidity and to shorten the protracted course associated with infection. With the infected viable grafts, efforts at salvaging the graft with multiple debridements and systemic antibiotics were rewarding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625574     DOI: 10.1097/00003086-199602000-00022

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  3 in total

1.  Surgical management of pilon fractures with large segmental bone defects using fibular strut allografts: a report of two cases.

Authors:  Weon-Yoo Kim; Jong-Hun Ji; Sang-Eun Park; Young-Yul Kim; Jae Jung Jeong; Hyun-Taek Kang
Journal:  Eur J Orthop Surg Traumatol       Date:  2011-03-25

Review 2.  Allograft Bone as Antibiotic Carrier.

Authors:  Heinz Winkler; Peter Haiden
Journal:  J Bone Jt Infect       Date:  2017-01-01

3.  Treatment of chronic orthopaedic infection.

Authors:  Heinz Winkler
Journal:  EFORT Open Rev       Date:  2017-05-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.